Clinical Core
临床核心
基本信息
- 批准号:10909444
- 负责人:
- 金额:$ 61.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-15 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:African AmericanAfrican American populationAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer&aposs disease therapeuticAutopsyBiological MarkersBrainClinicClinicalClinical TrialsCognitiveCollaborationsCollectionCommunitiesComplexDataData CollectionData SetDeliriumDementiaDevelopmentDiseaseElderlyEnrollmentFosteringFutureGeneticGoalsImageIndividualInfrastructureInjuryInstitutionInterventionLeadershipMRI ScansMagnetic Resonance ImagingMemoryNational Institute on AgingParticipantPathway interactionsPatient RecruitmentsPatientsPhasePreventionProceduresProtocols documentationQualifyingRecruitment ActivityRegistriesResearchResearch ActivityResearch InstituteResearch PersonnelRiskSamplingSiteTissuesTrainingTraining Supportcareerclinical centercohortcooperative studydata resourcedata sharinggenomic datainterestmembermild cognitive impairmentneuroimagingneuropathologynext generationnoveloutreachparticipant retentionpatient engagementpharmacologicpre-clinicalpreservationprogramsrecruitrepositoryresiliencetelephone based
项目摘要
PROJECT SUMMARY – CLINICAL CORE
The Exploratory Vanderbilt Alzheimer’s Disease Research Center (VADRC) Clinical Core will support local and
national Alzheimer’s disease research activities. Under the direction of Dr. Paul Newhouse, the Clinical Core
will enhance existing institutional infrastructure to engage and recruit older adults into Alzheimer’s disease and
related dementia research opportunities to support creating a future P30 Outreach and Recruitment Core.
Recruitment activities will build upon the existing 4000+ member Alzheimer’s Disease Research Registry and
focus on recruiting memory clinic patients and community-dwelling older adults interested in biomarker-focused
Alzheimer’s disease research opportunities. A strong emphasis will be placed on partnering with the
Vanderbilt-Meharry Alliance for outreach and engagement in the local African American community with a
focus on enhancing biomarker and autopsy participation. The Clinical Core will be responsible for establishing
and annually following a “proof of concept” cohort of 150 well-characterized participants age 60 and older who
are cognitively unimpaired or meet established criteria for mild cognitive impairment or Alzheimer’s disease.
Leveraging well-established protocols and extensive local infrastructure, we will collect detailed clinical,
cognitive, neuroimaging, genetic, and biospecimen data. These data will support our Center’s thematic
emphasis on prevention targets, large-scale discovery, and pharmacological interventions that collectively
emphasize non-amyloid pathways of injury commonly co-occurring with core Alzheimer’s disease pathology.
The Clinical Core will engage cohort participation in antemortem brain donation assent, and a scalable autopsy
protocol pipeline will be implemented to support a future P30 Neuropathology Core in collaboration with the
Rush Alzheimer’s Disease Research Center. The Clinical Core will support local and national research efforts
in Alzheimer’s disease by fostering collaborations and sharing data locally and nationally. Data and
biospecimens will be collected in a uniform manner according to current best-practices and shared with the
National Alzheimer’s Coordinating Center, the National Centralized Repository for Alzheimer’s Disease and
Related Dementias, and the National Institute on Aging Genetics of Alzheimer’s Disease Storage Site. The
Clinical Core will maximize local research initiatives by distributing clinical, cognitive, neuroimaging, genetic,
and biospecimen data to qualified investigators and maximizing Clinical Core cohort participation in
investigator initiated and multi-site studies. Finally, the Clinical Core will support training the next generation of
Alzheimer’s disease clinicians and investigators by providing participants, data, biospecimens, collaboration,
and leadership opportunities. Our interdisciplinary Clinical Core investigators have demonstrated expertise and
a proven track record in participant recruitment and retention as well as complex protocol implementation.
Thus, the Clinical Core will be a successful focal point of the VADRC in supporting both local and national
Alzheimer’s disease research activities.
项目摘要 – 临床核心
探索性范德比尔特阿尔茨海默病研究中心 (VADRC) 临床核心将支持当地和
在临床核心 Paul Newhouse 博士的指导下开展国家阿尔茨海默病研究活动。
将加强现有的机构基础设施,以吸引和招募老年人来治疗阿尔茨海默病,
相关的痴呆症研究机会,以支持创建未来的 P30 外展和招聘核心。
招募活动将以现有 4000 多名阿尔茨海默病研究注册中心成员为基础,
专注于招募对生物标志物感兴趣的记忆诊所患者和社区老年人
阿尔茨海默氏病的研究机会将重点放在与该组织的合作上。
范德比尔特-梅哈里联盟致力于在当地非裔美国人社区进行外展和参与,
重点关注加强生物标志物和尸检参与。临床核心将负责建立。
每年都会对由 150 名 60 岁及以上的特征鲜明的参与者组成的“概念验证”队列进行跟踪研究
认知能力未受损或符合轻度认知障碍或阿尔茨海默病的既定标准。
利用完善的协议和广泛的当地基础设施,我们将收集详细的临床、
认知、神经影像、遗传和生物样本数据将支持我们中心的主题。
强调预防目标、大规模发现和药物干预,
强调通常与阿尔茨海默病核心病理学同时发生的非淀粉样蛋白损伤途径。
临床核心将参与死前大脑捐赠同意和可扩展的尸检
将与以下组织合作实施协议管道以支持未来的 P30 神经病理学核心
拉什阿尔茨海默病研究中心将支持地方和国家的研究工作。
通过促进本地和全国范围内的合作和数据共享来治疗阿尔茨海默病。
生物样本将根据当前最佳实践以统一方式收集并与
国家阿尔茨海默病协调中心、国家阿尔茨海默病中央存储库和
相关痴呆症,以及国家衰老遗传学研究所阿尔茨海默病存储站点。
临床核心将通过分配临床、认知、神经影像、遗传、
和生物样本数据给合格的研究人员,并最大限度地参与临床核心队列
最后,临床核心将支持培训下一代。
阿尔茨海默病教区居民和研究人员通过提供参与者、数据、生物样本、协作、
我们的跨学科临床核心研究人员展示了专业知识和领导机会。
在参与者招募和保留以及复杂协议实施方面拥有良好的记录。
因此,临床核心将成为 VADRC 支持地方和国家的成功焦点
阿尔茨海默病研究活动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL A. NEWHOUSE其他文献
PAUL A. NEWHOUSE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL A. NEWHOUSE', 18)}}的其他基金
The cholinergic integrity in Down syndrome in association with aging, Alzheimer's disease pathology, and cognition
唐氏综合症的胆碱能完整性与衰老、阿尔茨海默病病理学和认知的关系
- 批准号:
10353561 - 财政年份:2022
- 资助金额:
$ 61.9万 - 项目类别:
Multisensory Processing Across Lifespan and Links to Cognition
整个生命周期的多感官处理及其与认知的联系
- 批准号:
8576040 - 财政年份:2013
- 资助金额:
$ 61.9万 - 项目类别:
Multisensory Processing Across Lifespan and Links to Cognition
整个生命周期的多感官处理及其与认知的联系
- 批准号:
8703646 - 财政年份:2013
- 资助金额:
$ 61.9万 - 项目类别:
ESTROGEN EFFECTS ON CHOLINERGIC FUNCTION IN OLDER WOMEN
雌激素对老年女性胆碱能功能的影响
- 批准号:
8166965 - 财政年份:2010
- 资助金额:
$ 61.9万 - 项目类别:
PHYSICAL ACTIVITY, TESTOSTERONE AND COGNITION IN OLDER MEN
老年男性的体力活动、睾酮和认知
- 批准号:
8166979 - 财政年份:2010
- 资助金额:
$ 61.9万 - 项目类别:
ESTROGEN EFFECTS ON CHOLINERGIC FUNCTION IN OLDER WOMEN
雌激素对老年女性胆碱能功能的影响
- 批准号:
8166991 - 财政年份:2010
- 资助金额:
$ 61.9万 - 项目类别:
A FMRI PILOT STUDY OF ESTROGEN AND CHOLINERGIC SYSTEM IN POST-MENOPAUSE
绝经后雌激素和胆碱能系统的 FMRI 试点研究
- 批准号:
8166967 - 财政年份:2010
- 资助金额:
$ 61.9万 - 项目类别:
相似海外基金
Developing Real-world Understanding of Medical Music therapy using the Electronic Health Record (DRUMMER)
使用电子健康记录 (DRUMMER) 培养对医学音乐治疗的真实理解
- 批准号:
10748859 - 财政年份:2024
- 资助金额:
$ 61.9万 - 项目类别:
Sleep and Cardiometabolic Subgroup Discovery and Risk Prediction in United States Adolescents and Young Adults: A Multi-Study Multi-Domain Analysis of NHANES and NSRR
美国青少年和年轻人的睡眠和心脏代谢亚组发现和风险预测:NHANES 和 NSRR 的多研究多领域分析
- 批准号:
10639360 - 财政年份:2023
- 资助金额:
$ 61.9万 - 项目类别:
Hospice exposure and utilization among older African Americans with ADRD and their decisional support persons
患有 ADRD 的老年非洲裔美国人及其决策支持人员的临终关怀暴露和利用
- 批准号:
10679558 - 财政年份:2023
- 资助金额:
$ 61.9万 - 项目类别:
The Role of Lipids in Alzheimer's Disease and Related Dementias among Black Americans: Examining Lifecouse Mechanisms
脂质在美国黑人阿尔茨海默病和相关痴呆中的作用:检查生命机制
- 批准号:
10643344 - 财政年份:2023
- 资助金额:
$ 61.9万 - 项目类别:
Elucidating novel epigenetic modifications implicated in multiple myeloma risk disparities
阐明与多发性骨髓瘤风险差异相关的新型表观遗传修饰
- 批准号:
10912191 - 财政年份:2023
- 资助金额:
$ 61.9万 - 项目类别: